Directly Administered Antiretroviral Therapy (DAART) Among HIV-1infected Injecting Drug Users (IDUs) in Chennai, India

NCT ID: NCT00709007

Last Updated: 2015-04-15

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2/PHASE3
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-07-31
• Study Completion Date: 2011-07-31

Brief Summary

Though the HIV epidemic in India is predominantly among heterosexual populations, it is estimated that there are approximately 1.1 million injection drug users (IDUs) in India with HIV prevalence as high as 64% among IDUs in certain cities. In April 2004, the government of India launched a free-antiretroviral therapy roll-out program aimed at initiating 100,000 persons on HAART. Similar guidelines are currently being followed for the delivery and choice of HAART for IDU and non-IDU populations. However, IDUs have certain issues that complicate the delivery of HAART that need to be addressed by delivery programs such as delayed access to care, poor perceived adherence, and more rapid disease progression. This proposal will assess the feasibility and effectiveness of directly administered antiretroviral therapy (DAART) in conjunction with opioid substitution as a mode of delivery of HAART to IDUs in Chennai, India. To evaluate this objective we will conduct a randomized controlled pilot study of DAART vs self-administered therapy (SAT) among 100 HIV-1 infected treatment naïve IDUs who are enrolled in an opioid substitution program in Chennai and compare the following outcomes between the two arms: Primary Endpoint: Proportion of participants with viral load (VL) <400 copies/ml at 24 and 48 weeks; Secondary Endpoints: (1) Incidence of mortality and AIDS-defining illnesses at 24 and 48 weeks, (2) Changes in absolute CD4+ count from baseline at 24 and 48 weeks, and (3) Incidence of antiretroviral drug resistance at 24 and 48 weeks. Intention-to-treat analyses will be used. The study objective is in line with the priority areas identified in the Indian National AIDS Control Program Phase III (NACP III) and the results of this study will help inform the government of India on appropriate modes of delivery of HAART to IDUs. This study will also be among the first studies to be conducted in India to evaluate two different modes of delivery of HAART to IDUs.

Conditions

HIV Infections; Heroin Dependence

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

DAART

Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.

Group Type: EXPERIMENTAL

Directly Administered Antiretroviral Therapy (DAART)

Intervention Type: BEHAVIORAL

Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.

SAT

Participants take their HIV medications on their own but visit the clinic for opioid agonist substitution therapy.

Group Type: ACTIVE_COMPARATOR

SAT

Intervention Type: BEHAVIORAL

Participants take their HIV medications by themselves.

Interventions

Directly Administered Antiretroviral Therapy (DAART)

Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.

Intervention Type: BEHAVIORAL

SAT

Participants take their HIV medications by themselves.

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

1. 18 years of age or older

2. Provide written informed consent

3. Permanent residence should be less than or equal to 15 kms (9.5 miles) from the YRGCSAR clinic

4. Be an injection drug user (by self-report)

5. Satisfy criteria for opioid dependence as per the DSM-IV criteria (see Appendix)

6. Urine screening must test positive for presence of opioids

7. Documented evidence of HIV infection (double ELISA: Murex HIV-1.2.O, Abbott Murex, UK and Vironostika® HIV Uni-form II Ag/Ab, Biomérieux, The Netherlands)

8. Be ART naïve (by self-report)

9. If female of childbearing potential (all of the following)

• Have a negative urine pregnancy test
• Be willing to use barrier based or oral contraceptive for the duration of the study if sexually active.

10. Satisfy Indian National Guidelines for initiation of HAART (any of the following)

• Absolute CD4+ count < 200 cells/ µl
• AIDS-defining illness with any CD4+ count
• Absolute CD4+ count between 200 - 350 cell/ µl with HIV-related symptoms

Exclusion Criteria

1. Requires a liquid preparation of ART or ART needs to be dosed more than twice daily

2. Indicates an intention to migrate in the next 48 weeks

3. Clinical or radiological signs of active tuberculosis

4. Any medical or psychiatric condition that the study physician believes to be a contraindication to study participation.

5. Enrolled in another HIV treatment program

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role: collaborator

Johns Hopkins University

OTHER

Sponsor Role: lead

Responsible Party

Johns Hopkins University School of Medicine

Principal Investigators

Gregory M Lucas, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

Johns Hopkins University School of Medicine, USA

Locations

YR Gaitonde Centre for Substance Abuse-Related Research (YRGCSAR)

Chennai, Tamil Nadu, India

Countries

India

Other Identifiers

R01DA018577-03S1

Identifier Type: NIH

Identifier Source: org_study_id

View Link